Multiple Sclerosis Has Dramatically Superior Disease-Modifying Treatment Options Compared to ALS
The treatment landscape for MS versus ALS represents a stark contrast: MS has multiple highly effective disease-modifying therapies that can achieve complete disease suppression in many patients, while ALS has only modest disease-slowing agents with minimal impact on survival and function.
Disease-Modifying Therapies: A Fundamental Difference
Multiple Sclerosis Treatment Arsenal
MS benefits from an extensive array of disease-modifying therapies (DMTs) spanning 11 different drug classes 1. The most striking evidence comes from the MIST trial, where autologous hematopoietic stem cell transplantation (AHSCT) achieved 90% progression-free survival at 5 years versus 25% with standard DMTs 2. Even among conventional therapies, high-efficacy DMTs including:
- Alemtuzumab
- Natalizumab
- Ocrelizumab
- Ofatumumab
- Cladribine
These agents can achieve "no evidence of disease activity" (NEDA-3) in substantial proportions of patients—meaning no relapses, no disability progression, and no new MRI lesions 2. The MIST trial demonstrated 78% of AHSCT patients achieved NEDA-3 at 5 years versus only 3% with standard DMTs 2.
For relapsing-remitting MS, AHSCT is now endorsed as standard of care for treatment-refractory disease by multiple international societies 2, with the potential to fundamentally reset the immune system and provide durable disease control.
ALS Treatment Limitations
In stark contrast, ALS has only three FDA-approved disease-modifying agents, all with marginal benefits 3:
- Riluzole: Offers only 36% higher probability of survival compared to placebo, translating to approximately 2-3 months of extended survival 4
- Edaravone: Showed 1.44 point lower decline on ALSFRS-R score, but this difference was not statistically significant in network meta-analysis 4
- Sodium phenylbutyrate/taurursodiol (PB-TURSO): Conditionally approved in Canada in 2022, showing modest slowing of disease progression 3
Critically, none of these agents halt or reverse ALS progression—they merely slow decline marginally 5. Network meta-analysis comparing all ALS interventions found no statistically significant differences between any treatments when compared to each other 4.
Treatment Goals: Suppression vs. Slowing
MS: Achieving Disease Suppression
The treatment paradigm in MS has shifted from "slowing progression" to achieving complete disease suppression with NEDA as the target 1. Early, aggressive treatment with high-efficacy DMTs can:
- Prevent relapses entirely
- Stop new lesion formation on MRI
- Halt disability progression
- In some cases with AHSCT, reverse disability (sustained disability improvement documented in secondary progressive MS) 2
MS patients treated early with high-efficacy therapies can expect near-normal life expectancy and quality of life 2.
ALS: Modest Symptom Management
ALS treatment remains fundamentally palliative. The 2024 National Academies report emphasizes making ALS "livable" rather than curable, focusing on 6:
- Multidisciplinary supportive care
- Respiratory support devices
- Nutritional management
- Communication aids
- End-of-life planning
The goal in ALS is extending survival by months and maintaining quality of life, not preventing disease progression 5, 7.
Pathophysiology Explains the Treatment Gap
MS is primarily an autoimmune inflammatory disease where the immune system attacks myelin. This makes it amenable to immunomodulation and immunosuppression 8. AHSCT works by completely ablating and resetting the pathogenic immune system 2.
ALS involves motor neuron degeneration through multiple mechanisms (glutamate toxicity, oxidative stress, protein aggregation, mitochondrial dysfunction) that are far less tractable to pharmacologic intervention 8, 3. Once motor neurons die, they cannot be replaced or regenerated with current therapies.
Clinical Implications
For MS Patients
- Multiple treatment options exist across the disease spectrum
- Early aggressive treatment prevents long-term disability
- Treatment can be escalated from moderate-efficacy to high-efficacy DMTs
- AHSCT offers potential for durable remission in refractory cases 2
- Progressive MS with inflammatory activity can still benefit from treatment 2
For ALS Patients
- Treatment options remain severely limited 5
- Focus must be on comprehensive multidisciplinary care rather than disease modification 6
- Respiratory support and nutritional interventions are as important as pharmacotherapy 7
- Clinical trial participation should be strongly encouraged given the limited approved options 3
Common Pitfall
Do not conflate "neurodegenerative disease" with similar treatment potential. While both MS and ALS involve neurodegeneration, MS has a dominant inflammatory component that is highly treatment-responsive, whereas ALS neurodegeneration is largely irreversible with current therapies 8. The misdiagnosis between these conditions significantly impacts prognosis and quality of life 8.
The treatment gap between MS and ALS represents one of the most dramatic disparities in modern neurology—MS has evolved from an untreatable disease to one with multiple curative-intent options, while ALS remains stubbornly resistant to meaningful disease modification despite decades of research 3, 5.